lenacapavir
Trial Shows Lenacapavir + bNAbs As Possible HIV Treatment
New longer-acting treatment options for HIV may be on the horizon.
JULY 31, 2025
FDA Approves Yeztugo for HIV PrEP Lasting 6 Months
The FDA approved lenacapavir, an injectable HIV-1 capsid inhibitor, to be used as PrEP to reduce the risk of ...
JUNE 18, 2025
Twice-Yearly Lenacapavir Sets a New PrEP Standard
The results of an interim analysis from a second pivotal phase 3 clinical trial investigating the use of ...
OCTOBER 25, 2024
Twice-Yearly Lenacapavir 100% Effective in Preventing HIV Among Cisgender Women
An interim analysis of PURPOSE 1 found twice-yearly lenacapavir was superior to once-daily oral FTC/TDF in ...
JULY 24, 2024
Oral Bridging of Lenacapavir Maintains Viral Suppression Among HIV Patients
Oral bridging of lenacapavir enabled patients to maintain viral suppression of their HIV after missed doses of ...
JULY 27, 2023
Investigational Combo Lenacapavir Plus bNAbs Would Push HIV Treatment to Twice Yearly
The combination of lenacapavir with two broadly neutralizing antibodies was generally well tolerated with high ...
FEBRUARY 23, 2023
FDA Approves Sunlenca for Adults With Resistant HIV
The FDA approved lenacapavir, a first-in-class, long-acting HIV capsid inhibitor, which is injected twice ...
DECEMBER 22, 2022
No Approval for Lenacapavir Due to Vial Compatibility Issues
The FDA issued a complete response letter for the New Drug Application for lenacapavir, an investigational, ...
MARCH 3, 2022
